NRK1 Antibody

What is NRK1 and what is its role in cellular metabolism?

NRK1, also known as Nicotinamide Riboside Kinase 1, is an enzyme that plays a crucial role in cellular metabolism by catalyzing the conversion of nicotinamide riboside (NR) into nicotinamide mononucleotide (NMN), a key precursor in the synthesis of nicotinamide adenine dinucleotide (NAD+). This conversion is essential for maintaining adequate NAD+ levels, which are vital for numerous biological processes including energy production, DNA repair, and cell signaling . The enzyme is part of the Uridine kinase protein family and is widely expressed across many tissue types. NRK1 is specifically involved in the phosphorylation of nicotinic acid riboside (NaR) as well, forming nicotinic acid mononucleotide (NaMN) . Research has also revealed that NRK1 contributes to cancer treatment strategies by phosphorylating certain anti-cancer drugs such as tiazofurin and 3-deazaguanosine, transforming them into toxic NAD+ analogs that inhibit guanine nucleotide biosynthesis .

What types of NRK1 antibodies are currently available for research applications?

Researchers have access to a diverse array of NRK1 antibodies optimized for different experimental applications. The primary types include:

• Monoclonal Antibodies: These include mouse monoclonal IgG2a kappa light chain antibodies that detect NRK1 protein from multiple species (mouse, rat, and human) .

• Polyclonal Antibodies: Including rabbit polyclonal antibodies designed for various applications .

• Conjugated Antibodies: NRK1 antibodies are available in both non-conjugated forms and various conjugated forms including:

  • Agarose-conjugated for immunoprecipitation

  • Horseradish peroxidase (HRP)-conjugated for enhanced chemiluminescence detection

  • Fluorescent conjugates including phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® variants for fluorescence-based applications

Additionally, antibody-binding protein combinations (such as m-IgG Fc BP-HRP bundles) are available for specialized detection protocols . This variety allows researchers to select the most appropriate antibody format based on their specific experimental requirements and detection systems.

What are the validated applications for NRK1 antibodies?

NRK1 antibodies have been validated for several immunodetection techniques:

• Western Blotting (WB): This is the most widely used application for NRK1 antibodies, allowing for detection of NRK1 protein expression levels in cell and tissue lysates .

• Immunoprecipitation (IP): NRK1 antibodies, particularly agarose-conjugated variants, can efficiently isolate NRK1 protein complexes from cellular extracts .

• Immunofluorescence (IF): For visualizing NRK1 localization within cells using fluorescence microscopy .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of NRK1 in solution .

• Immunohistochemistry with Paraffin-embedded tissues (IHC-P): Some antibodies like the rabbit polyclonal NRK1 antibody have been specifically validated for detecting NRK1 in fixed tissue sections .

Different antibodies may perform optimally in specific applications, so it is important to select one that has been validated for your particular experimental approach. For example, some antibodies may work well for western blotting but might not be ideal for immunohistochemistry applications .

How does NRK1 regulate NAD+ biosynthesis and what is its importance in experimental models?

NRK1 plays a critical, rate-limiting role in NAD+ biosynthesis from exogenous precursors. Studies using genetic gain- and loss-of-function models have demonstrated that NRK1 is necessary for the utilization of exogenous nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) for NAD+ synthesis, while its role in processing other NAD+ precursors such as nicotinamide or nicotinic acid is dispensable . This specificity makes NRK1 a potential therapeutic target for conditions associated with NAD+ depletion.

Research has revealed that cells expressing NRK1 show dose-dependent increases in NAD+ accumulation when exposed to NR, with effects visible at concentrations as low as 100 μM and reaching maximal levels at approximately 1 mM . Experiments with catalytically inactive NRK1 mutants (NRK1-D36A) confirmed that the enzymatic activity of NRK1 is essential for NR-induced NAD+ synthesis, as these mutants failed to enhance NAD+ production despite being expressed at levels comparable to the wild-type protein .

Interestingly, NRK1's role extends beyond intracellular metabolism. Using stable isotope-labeled compounds, researchers have confirmed that extracellular NMN must first be metabolized to NR before cellular uptake and subsequent conversion to NAD+ . This finding explains the overlapping metabolic effects observed with both NR and NMN supplementation in various disease models, suggesting that targeting NRK1 could be a unified approach for enhancing NAD+ production regardless of which precursor is administered.

What structural and functional differences exist between NRK1 and NRK2?

While NRK1 and NRK2 share similar enzymatic functions in NAD+ metabolism, they exhibit distinct patterns of expression and potentially different regulatory mechanisms:

• Expression Patterns: NRK1 is widely expressed across multiple tissue types, whereas NRK2 shows pronounced tissue-specific expression, being primarily detected in muscle tissue . This differential expression suggests specialized roles in tissue-specific NAD+ metabolism.

• Protein Stability: Experimental evidence indicates that NRK2 may require muscle-specific factors for stability. In overexpression systems, NRK2 protein was difficult to detect despite robust increases at the mRNA level, while NRK1 was effectively overexpressed and stable . This suggests different post-translational regulation between the two enzymes.

• Catalytic Activity: Despite lower protein expression, NRK2 overexpression can drive significant increases in NR-induced NAD+ synthesis, suggesting high catalytic efficiency . Both enzymes contain critical catalytic residues, with mutations at positions D36 and E98 in NRK1 and D35 and D100 in NRK2 affecting protein stability and function .

• Protein Size and Structure: The human NRK1 canonical protein consists of 199 amino acid residues with a molecular mass of 23.2 kDa . Up to two different isoforms have been reported for NRK1, resulting from alternative splicing . Comprehensive structural comparisons between NRK1 and NRK2 would provide further insights into their distinct functions and regulatory mechanisms.

Understanding these differences is crucial for designing targeted experimental approaches and interpreting results when studying NAD+ metabolism in different tissue contexts.

How can NRK1 antibodies be used to study NAD+ metabolism in aging and disease models?

NRK1 antibodies provide powerful tools for investigating NAD+ metabolism in aging and disease models through several methodological approaches:

These applications are particularly relevant given the emerging evidence that NAD+ precursor supplementation, such as with NMN or NR, can protect against metabolic disease, neurodegenerative disorders, and age-related physiological decline in mammals .

What are the optimal conditions for using NRK1 antibodies in Western blotting?

For optimal results when using NRK1 antibodies in Western blotting, researchers should consider the following protocol recommendations:

• Sample Preparation:

  • Use fresh tissue or cell lysates prepared in RIPA or similar buffers containing protease inhibitors

  • Determine appropriate protein concentration (typically 20-50 μg total protein per lane)

  • Denature samples at 95°C for 5 minutes in Laemmli buffer containing reducing agent

• Gel Electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal resolution of NRK1 (23.2 kDa)

  • Include molecular weight markers that cover the 20-30 kDa range

• Transfer Conditions:

  • PVDF membranes are generally preferred over nitrocellulose for detecting NRK1

  • Transfer at 100V for 1 hour in cold transfer buffer or 30V overnight at 4°C

• Blocking:

  • Block membranes with 5% non-fat dry milk or 5% BSA in TBST for 1 hour at room temperature

• Primary Antibody Incubation:

  • Dilute NRK1 antibodies according to manufacturer recommendations (typical working concentrations are 1:500 to 1:2000)

  • Incubate overnight at 4°C with gentle agitation

• Detection System:

  • For HRP-conjugated NRK1 antibodies, proceed directly to detection after washing

  • For non-conjugated antibodies, use appropriate species-specific secondary antibodies (typical dilution 1:5000 to 1:10000)

  • Enhanced chemiluminescence (ECL) detection systems are recommended

• Positive Controls:

  • Include lysates from tissues known to express high levels of NRK1, such as liver and kidney

• Expected Results:

  • NRK1 should be detected at approximately 23.2 kDa

  • Validation of antibody specificity can be performed using lysates from NRK1 knockdown or overexpression models

These optimized conditions should result in specific detection of NRK1 protein with minimal background or non-specific binding.

How can researchers validate the specificity of NRK1 antibodies?

Validating antibody specificity is crucial for ensuring reliable experimental results. For NRK1 antibodies, researchers should consider implementing the following validation strategies:

• Genetic Controls:

  • Use cell lines or tissues with genetic knockdown of NRK1 (siRNA, shRNA, or CRISPR-Cas9) as negative controls

  • Use overexpression systems such as the F3T3-NRK1 cell line as positive controls

  • Compare results with catalytically inactive mutants (e.g., NRK1-D36A) to distinguish between specific binding and background

• Peptide Competition Assays:

  • Pre-incubate the NRK1 antibody with excess immunizing peptide before application to the sample

  • Specific signals should be significantly reduced or eliminated in peptide-blocked samples

• Multiple Antibody Validation:

  • Use multiple antibodies that recognize different epitopes of NRK1

  • Consistent results across different antibodies increase confidence in specificity

• Cross-Species Reactivity:

  • Verify reactivity across specified species (e.g., mouse, rat, human) as claimed by manufacturers

  • Discrepancies in cross-reactivity may indicate specificity issues

• Mass Spectrometry Confirmation:

  • Perform immunoprecipitation using NRK1 antibodies followed by mass spectrometry analysis

  • Confirm that the precipitated protein is indeed NRK1

• Known Expression Pattern Comparison:

  • Compare observed expression patterns with established NRK1 expression data

  • NRK1 should show high expression in liver and kidney tissues

• Isoform Specificity:

  • Determine whether the antibody detects both reported isoforms of NRK1

  • This is particularly important when studying alternative splicing regulation

By implementing these validation strategies, researchers can ensure that their results reflect true NRK1 biology rather than artifacts from non-specific antibody binding.

What factors should researchers consider when selecting NRK1 antibodies for immunohistochemistry?

When selecting NRK1 antibodies for immunohistochemistry (IHC), researchers should consider several critical factors to ensure optimal results:

• Validated Applications:

  • Confirm that the antibody has been specifically validated for IHC-P (paraffin-embedded tissues)

  • Review published literature or manufacturer data showing successful IHC applications

• Fixation Compatibility:

  • Determine compatibility with your preferred fixation method (formalin, paraformaldehyde, etc.)

  • Some epitopes may be masked or destroyed by certain fixation protocols

• Species Reactivity:

  • Ensure the antibody recognizes NRK1 in your species of interest

  • Cross-reactivity information should be provided by manufacturers

• Clonality Considerations:

  • Monoclonal antibodies offer high specificity to a single epitope but may be more sensitive to epitope masking

  • Polyclonal antibodies can provide stronger signals by binding multiple epitopes but may have higher background

• Antigen Retrieval Requirements:

  • Determine whether heat-induced or enzymatic antigen retrieval is recommended

  • Optimize pH and buffer composition for antigen retrieval

• Detection System Compatibility:

  • Consider whether the primary antibody works best with particular detection systems (HRP/DAB, alkaline phosphatase, or fluorescence-based systems)

  • For fluorescent detection, select antibodies with appropriate conjugates or compatible species for secondary antibodies

• Dilution Optimization:

  • Start with manufacturer-recommended dilutions (typically 1:100 to 1:500 for IHC)

  • Perform dilution series to identify optimal signal-to-noise ratio

• Positive Control Tissues:

  • Include tissues known to express NRK1, such as liver, kidney, or placenta

  • Human placenta tissue has been successfully used with some NRK1 antibodies at 1:200 dilution

• Blocking Considerations:

  • Optimize blocking conditions to minimize background (serum type, concentration, and incubation time)

  • Consider specialized blocking for tissues with high endogenous biotin or peroxidase activity

By carefully evaluating these factors, researchers can select the most appropriate NRK1 antibody for their specific IHC application, tissue type, and detection system.

How should researchers interpret discrepancies between NRK1 mRNA and protein expression levels?

Researchers frequently encounter discrepancies between mRNA and protein expression levels of NRK1, which can complicate data interpretation. These discrepancies may arise from several biological and technical factors:

• Post-transcriptional Regulation:

  • Evidence from NRK1/NRK2 studies shows that despite high mRNA expression, protein levels may not correlate directly

  • microRNA regulation or RNA-binding proteins may affect mRNA stability or translation efficiency

• Post-translational Modifications and Protein Stability:

  • Research with NRK1 and NRK2 mutants (NRK1-E98A and NRK2-D100A) demonstrates that certain mutations can significantly affect protein accumulation despite normal mRNA expression

  • Protein half-life varies between tissues and may be influenced by cellular conditions

• Detection Method Sensitivity:

  • Western blot detection limits may prevent visualization of low-abundance proteins despite detectable mRNA

  • RT-qPCR has a broader dynamic range than protein detection methods, potentially creating apparent discrepancies

• Tissue-Specific Factors:

  • NRK2 studies suggest that tissue-specific factors may be required for protein stability

  • Similar mechanisms might affect NRK1 in certain cellular contexts

• Interpretation Guidelines:

  • When discrepancies occur, protein data should generally take precedence for functional interpretations

  • Compare protein expression to physiologically relevant tissues (e.g., comparing overexpression levels to endogenous levels in liver and kidney)

  • Consider using multiple antibodies that recognize different epitopes to confirm protein expression patterns

• Experimental Validation Approaches:

  • Use proteasome inhibitors to determine if low protein levels result from rapid degradation

  • Employ polysome profiling to assess translation efficiency of NRK1 mRNA

  • Consider pulse-chase experiments to determine protein half-life in different contexts

Understanding these factors can help researchers properly interpret experimental results and design appropriate controls when studying NRK1 expression and function.

What controls should be included when studying NRK1 enzymatic activity?

When investigating NRK1 enzymatic activity, researchers should include several critical controls to ensure reliable and interpretable results:

• Positive and Negative Enzymatic Controls:

  • Positive control: Recombinant active NRK1 protein with known activity

  • Negative control: Heat-inactivated enzyme or catalytically inactive mutants (e.g., NRK1-D36A)

• Substrate Controls:

  • Include no-substrate controls to establish baseline measurements

  • Use purified NR and other potential substrates (NMN, nicotinamide, nicotinic acid) to confirm substrate specificity

  • Consider isotope-labeled substrates for tracking metabolic conversions

• Inhibitor Controls:

  • Include known inhibitors of related kinases to establish assay specificity

  • Test concentration-dependent inhibition to confirm on-target effects

• Genetic Manipulation Controls:

  • Compare wild-type cells/tissues with NRK1 knockout or overexpression models

  • Include heterozygous models to assess dose-dependent effects of NRK1 activity

  • Use transient overexpression systems alongside stable cell lines (e.g., F3T3-NRK1) to control for adaptation effects

• Technical and Methodological Controls:

  • Include no-enzyme controls for background activity from other cellular components

  • Perform time-course experiments to ensure measurements are taken during the linear phase of enzymatic activity

  • Validate assay conditions (pH, temperature, cofactor requirements) using recombinant NRK1

• Physiological Relevance Controls:

  • Compare enzymatic activity in cell culture to tissue extracts where NRK1 is endogenously expressed

  • Assess enzymatic activity under various physiological and pathological conditions

• Activity Measurement Validation:

  • Use multiple methods to measure enzyme activity (e.g., HPLC detection of reaction products, coupled enzyme assays, ADP formation assays)

  • Confirm that measured NAD+ levels correlate with expected changes in NRK1 activity

Implementing these controls will help ensure that observed effects on NAD+ metabolism are specifically attributable to NRK1 activity rather than to other enzymes or experimental artifacts.

How does extracellular processing of NAD+ precursors influence experimental design?

Recent discoveries about extracellular processing of NAD+ precursors have significant implications for experimental design when studying NRK1 function and NAD+ metabolism:

• NMN to NR Conversion Requirement:

  • Research using stable isotope-labeled compounds has confirmed that extracellular NMN must be metabolized to NR before cellular uptake and conversion to NAD+

  • This finding necessitates reconsideration of experimental designs assuming direct cellular uptake of NMN

• Medium Composition Considerations:

  • Standard culture media containing nicotinamide (NAM) may influence baseline NAD+ levels

  • Experiments should be designed with defined media compositions to accurately assess the effects of exogenous precursors

• Concentration and Dosing Regimens:

  • Dose-response studies with NR show effects at concentrations as low as 100 μM, with maximal effects at approximately 1 mM

  • Similar concentration ranges should be considered when designing experiments with NMN due to its extracellular conversion to NR

• Tissue-Specific Processing:

  • Different tissues may vary in their capacity for extracellular processing of NAD+ precursors

  • Experimental designs should account for tissue-specific expression of ectoenzymes that may affect precursor metabolism

• In Vivo vs. In Vitro Considerations:

  • The extracellular environment in vivo is more complex than cell culture conditions

  • Serum components may contain enzymes that process NAD+ precursors differently than in defined media

• Methodological Implications:

  • Include extracellular fluid analysis in experimental designs

  • Consider using specific inhibitors of ectoenzymes to distinguish between intracellular and extracellular processing

  • Employ cell-impermeable precursors as controls to confirm the requirement for extracellular processing

• Timing Considerations:

  • The kinetics of extracellular processing may introduce time-dependent effects

  • Time-course experiments should be designed to capture both immediate and delayed responses to precursor supplementation

Understanding these factors is crucial for accurately interpreting results and designing experiments that account for the complex metabolism of NAD+ precursors in biological systems.

What are the key considerations for using NRK1 antibodies in multi-omics research approaches?

As multi-omics approaches become increasingly important in understanding complex biological systems, researchers should consider several key factors when incorporating NRK1 antibodies into these integrated research strategies:

• Proteomics Integration:

  • For proteomics studies, validate NRK1 antibody specificity using immunoprecipitation followed by mass spectrometry

  • Consider using multiple antibodies targeting different epitopes to increase confidence in protein identification

  • Use quantitative proteomics approaches (e.g., SILAC, TMT labeling) to correlate NRK1 protein levels with other proteins in NAD+ metabolism pathways

• Transcriptomics Correlation:

  • Design experiments to simultaneously measure NRK1 mRNA (via RNA-seq or qPCR) and protein levels

  • Be aware that NRK1 mRNA and protein levels may not directly correlate, as observed in studies comparing NRK1 and NRK2

  • Use this integrated data to identify potential post-transcriptional regulatory mechanisms

• Phosphoproteomics Applications:

  • Investigate NRK1 phosphorylation status using phospho-specific antibodies when available

  • Consider how post-translational modifications might affect antibody binding and recognition

  • Correlate phosphorylation states with enzymatic activity measurements

• Interactomics Approaches:

  • Use NRK1 antibodies for co-immunoprecipitation studies to identify protein interaction networks

  • Validate interactions using reciprocal immunoprecipitation with antibodies against interacting partners

  • Consider proximity labeling approaches (BioID, APEX) as complementary methods to identify transient interactions

• Metabolomics Integration:

  • Correlate NRK1 protein levels detected by antibodies with metabolomics data focusing on NAD+ and related metabolites

  • Design experiments to track isotope-labeled metabolites while monitoring NRK1 protein levels

  • Use metabolomics data to validate the functional consequences of changes in NRK1 expression

• Spatial Omics Considerations:

  • For spatial proteomics, use immunofluorescence-compatible NRK1 antibodies

  • Correlate subcellular localization data with compartment-specific metabolomics

  • Consider multiplexed imaging approaches to simultaneously visualize NRK1 and interacting partners

• Data Integration Challenges:

  • Account for differences in dynamic range between omics platforms

  • Consider temporal aspects of different molecular events (transcription, translation, post-translational modifications)

  • Develop computational approaches to integrate antibody-based data with other omics datasets

By carefully considering these factors, researchers can effectively incorporate NRK1 antibodies into multi-omics research approaches to gain comprehensive insights into NAD+ metabolism regulation in health and disease.